A new era in protein quantification in clinical laboratories: Application of liquid chromatography-tandem mass spectrometry

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 543-544

  Hortin, Glen L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 GLYCOPROTEIN; PROTEIN;

CLINICAL LABORATORY; EDITORIAL; HUMAN; LIQUID CHROMATOGRAPHY; NONHUMAN; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

CARRIER PROTEINS; CHROMATOGRAPHY, LIQUID; CLINICAL CHEMISTRY TESTS; GLYCOPROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEINS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 34147211970     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.083857     Document Type: Editorial

References (15)

1. Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG. Quantification of Zn-α2-glycoprotein (ZAG) by LC-MS/MS: a potential serum biomarker for prostate cancer. Clin Chem 2007;53:673-8.
2. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37.
3. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Person TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
4. Julka S, Regnier F. Quantification in proteomics through stable isotope coding: a review. J Proteome Res 2004;3:350-63.
5. Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 2004;3:644-52.
6. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
7. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004;4:1175-86.
8. Beynon RJ, Doherty MK, Pratt JM, Gaskell SJ. Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. Nat Methods 2005;2:587-9.
9. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
10. Hortin GL, Jortani SA, Ritchie JC, Valdes RC, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22.
11. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 2005;357:113-22.
12. Hortin GL. Can mass spectrometric profiling meet desired standards of clinical laboratory practice? [Editorial]. Clin Chem 2005;51:3-5.
13. Sacks D for the ADA/EASD/IDF Working Group of the HbA1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 2005;51:681-3.
14. Rodriguez-Cabaleiro D, Stockl D, Kaufman JM, Fiers T, Thienpont LM. Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem 2006;52:1193-5.
15. Babic N, Larson TS, Grebe SK, Turner ST, Kumar R, Singh RJ. Application of liquid chromatography-mass spectrometry technology for early detection of microalbuminuria in patients with kidney disease. Clin Chem 2006;52: 2155-7.